Physician profile
Richard L Lindstrom
NPI 1740275908
$5,648,677.36
in general payments reported to CMS, 2019-2025
31 companies · $966K in 2025
The $966K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790K · 2020: $704K · 2021: $848K · 2022: $639K · 2023: $970K · 2024: $733K · 2025: $966K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.5M · Consulting Fee: $823K · Honoraria: $215K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Travel and Lodging: $13K · Food and Beverage: $5,466 · Entertainment: $250 · Gift: $88.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,507,125.68 |
| Consulting Fee | $823,077.39 |
| Honoraria | $215,008.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,818.44 |
| Travel and Lodging | $13,366.74 |
| Food and Beverage | $5,465.97 |
| Entertainment | $250.00 |
| Gift | $88.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,935,026.92 | 2022-2025 | Ophthalmic Instruments, Scoutpro Osmolarity System |
| Ocular Therapeutix, INC. | $1,569,217.86 | 2019-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,331,493.58 | 2019-2021 | |
| Lensar, INC. | $322,860.82 | 2019-2023 | Lensar Laser System |
| Tearlab Corp | $198,855.19 | 2019-2024 | Scoutpro Osmolarity System |
| Glaukos Corporation | $77,636.72 | 2019-2025 | Idose Tr, Travoprost Intraocular Implant - Idose, Idose |
| Alcon Research LLC | $54,699.38 | 2021-2025 | Centurion, Tryptyr, Acrysof Iq Panoptix Uv Iol |
| Alcon Vision LLC | $35,822.72 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Centurion |
| Harrow Eye, LLC | $35,295.35 | 2023-2025 | Vevye, Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $25,243.24 | 2019-2023 | Healon Duet Pro, Catalys System, Compact Intuitiv |
| Kala Pharmaceuticals, INC. | $17,146.09 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $14,898.84 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $14,649.69 | 2019-2021 | |
| Omeros Corporation | $7,572.14 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $2,463.33 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nordic Pharma, INC. | $1,225.00 | 2024 | Lacrifill |
| Shire North American Group INC | $1,200.00 | 2019 | |
| Allergan, INC. | $1,102.50 | 2020 | |
| Eyevance Pharmaceuticals LLC | $1,000.00 | 2019 | |
| Rxsight INC | $546.68 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
| Haag-Streit USA, INC. | $139.73 | 2022 | |
| Abbvie INC. | $114.13 | 2024 | |
| Quidel Corporation | $103.62 | 2019 | |
| Bausch Health US, LLC | $102.44 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $88.91 | 2025 | |
| The Cameron-Ehlen Group, INC. | $67.27 | 2019 | |
| Beaver-Visitec International, INC. | $38.58 | 2021 | |
| Dompe US, INC. | $33.53 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $33.10 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,693,054.04 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lindstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.